What do systematic reviews say?

Summary of findings table ‐ Aspiration/flush vs aspiration

Summary of findings table ‐ Aspiration/flush showed no clear difference in miscarriage rate ‐ total compared with aspiration (low certainty).

• Follicular flushing during oocyte retrieval in assisted reproductive techniques 2022 · Cochrane Headline outcomes only
  OR 1.98 [0.18, 22.22]
  1 study · 164 participants
  Low

Summary of findings table ‐ Aspiration/flush vs aspiration

• Follicular flushing during oocyte retrieval in assisted reproductive techniques 2022 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 1239 participants
  Very low

Summary of findings table ‐ Aspiration/flush vs aspiration

• Follicular flushing during oocyte retrieval in assisted reproductive techniques 2022 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 785 participants
  Low

Summary of findings table ‐ Aspiration/flush vs aspiration

• Follicular flushing during oocyte retrieval in assisted reproductive techniques 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 160 participants
  Low

Summary of findings table ‐ Aspiration/flush vs aspiration

Summary of findings table ‐ Aspiration/flush showed no clear difference in clinical pregnancy rate per woman randomised compared with aspiration (low certainty).

• Follicular flushing during oocyte retrieval in assisted reproductive techniques 2022 · Cochrane Headline outcomes only
  OR 1.13 [0.85, 1.51]
  7 studies · 939 participants
  Low

Summary of findings table ‐ Aspiration/flush vs aspiration

• Follicular flushing during oocyte retrieval in assisted reproductive techniques 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 3 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 183 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 147 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 208 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1250 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

Summary of findings table ‐ Systemic therapy showed no clear difference in change in grip strength from baseline to end of intervention compared with control (low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 1.08 [0.37, 3.17]
  1 study · 137 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 344 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

Summary of findings table ‐ Systemic therapy showed no clear difference in effect on discontinuation of aromatase inhibitors (AI) compared with control (low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 0.16 [0.01, 2.99]
  1 study · 147 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 44 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

It is very uncertain whether summary of findings table ‐ Systemic therapy changes incidence of AIMSS compared with control (very low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 0.82 [0.63, 1.06]
  2 studies · 240 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1099 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 295 participants
  Very low

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 61 participants
  Low